The goal of this observational study is to assess the oncological outcomes in patients diagnosed with grade 2 chondrosarcoma, treated with intralesional curettage, stratified into two cohorts: those subjected to follow up monitoring and those who have undergone subsequent surgical intervention.
Large resection of the tumor is considered the treatment of choice in patients affected by grade 2 chondrosarcoma. Nonetheless, a preoperative diagnosis of a lower grade lesion (ChS grade 1) is not infrequent, thus making these patients treated with intralesional curettage. Intralesional curettage is a type of surgery in which the pathological component is removed from the affected bone and the resulting bone defects can be filled with bone substitutes or bone cement. Bone cortexes are left in place like a shell. The results of this study could contribute to find the right therapeutic pathway in patients affected by grade 2 chondrosarcoma treated with intralesional curettage, in particular in patients who underwent further surgery (bone resection) or follow-up. Since outcome data are scarce in the literature, the results of this study could be used to assess the feasibility of a randomized controlled trial with the correct sample size. It is an explorative, spontaneous, non-profit, retrospective, observational study. It involves the pseudonymous data collection of all patients matching inclusion criteria. The data recorded in this study are extracted from the medical records of patients who regularly seek care from the medical unit during their routine clinical visits. Following a meticulous collection of patients' baseline data, the two therapeutic options (clinical monitoring or bone resection) in patients affected by grade 2 chondrosarcoma treated with intralesional curettage will be compared. Data related to demographics, histologic and treatment data will be collected. Oncologic follow-up data will be also collected. In particular, data related to local recurrences, distant metastasis and survival will be evaluated.
Study Type
OBSERVATIONAL
Enrollment
62
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy
Tumor recurrence(%)
It will be measured by: X-Rays, CT, MRI, PET CT scan
Time frame: 3 months, 6 months, 1 year, 2 years, 5 years, 10 years
distant metastasis (%)
It will be measured by: CT scan of the lungs, PET CT scan
Time frame: 3 months, 6 months, 1 year, 2 years, 5 years, 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.